Even at $2M+, ICER calls bluebird's potential gene therapy for blood disorder 'superior' to standard of care

The Institute for Clinical and Economic Review, a drug pricing watchdog, gave a measured thumbs up on Thursday morning to bluebird’s potentially expensive new gene therapy for a rare but debilitating blood disorder, which will go before an FDA advisory committee next Friday.